Financing channel feed

Rap­port, a clin­i­cal-stage neu­ro­science biotech, files for IPO

12 months ago
Startups

Aus­tralian ra­dio­phar­ma Telix launch­es bid for Nas­daq list­ing

12 months ago

GSK, UK gov­ern­ment bud­get £130M to fight glob­al an­timi­cro­bial re­sis­tance

12 months ago
Pharma

Ex­clu­sive: Gas­tro­pare­sis biotech Cin­Dome se­cures $40M for path to piv­otal tri­al

12 months ago
R&D

Up­dat­ed: Black­stone com­mits $300M to a for­mer Mer­ck an­ti­body for asth­ma, COPD

12 months ago
Deals

Up­dat­ed: Sands Cap­i­tal rais­es $555M for third life sci­ences fund

12 months ago
Startups

Car­olyn Bertozzi-found­ed Ly­cia Ther­a­peu­tics rais­es $106M to en­ter the clin­ic

Last year
Startups

New­Vale un­veils $167M fund to back phar­ma ser­vice providers and 'old ideas that are work­ing'

Last year
Outsourcing
Manufacturing

'At­tack JAK': Ajax se­cures $95M to test new JAK2 in­hibitor af­ter in­dus­try's string of myelofi­bro­sis deals

Last year
Startups

Up­dat­ed: France draws €2B+ re­search, man­u­fac­tur­ing in­vest­ment from Sanofi, Pfiz­er, As­traZeneca, GSK

Last year
Manufacturing

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Last year
Marketing

In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Last year
Startups

At­tovia reels in $105M from crossover in­vestors to run mul­ti­ple tri­als of I&I bi­o­log­ics

Last year
Startups

Aard­vark nabs $85M to tar­get hunger, not ap­petite, as it eyes 2026 NDA fil­ing

Last year
Startups

Dan­ish biotech nabs No­vo Hold­ings sup­port in seed round for com­ple­ment plat­form

Last year

Lon­nie Moul­der's Zenas clos­es a $200M Se­ries C to broad­en lead drug's au­toim­mune po­ten­tial

Last year

Flag­ship com­mits $50M to new start­up that scours vi­ral pro­teins for new drugs

Last year
Startups

Memo Ther­a­peu­tics re­fu­els with $22M to ex­pand tri­al for in­fec­tion-fight­ing an­ti­body in kid­ney trans­plant re­cip­i­ents

Last year

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

Last year
R&D

As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Last year
Startups

As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

Last year
Pharma
Cell/Gene Tx

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

Last year
Startups
Cell/Gene Tx

Biotech vets raise $67M to de­vel­op tar­get­ed ac­ti­va­tors for can­cer

Last year

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Last year
Startups
Deals
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times